Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL-2-like protein 2 is a 193-amino acid, anti-apoptotic mitochondrial protein encoded by the BCL2L2 gene on chromosome 14q11.2-q12. Most homologous to Bcl-xL, BCL2L2 (commonly called Bcl-w) acts as a pro-survival member of the BCL-2 family, forming homo- and heterodimers to inhibit cell death under cytotoxic stress. It is critical for the survival of NGF- and BDNF-dependent neurons and for adult spermatogenesis. Overexpression contributes to tumorigenesis and resistance to cancer therapy by preventing apoptosis. BCL2L2 is targeted by BH3-mimetic drugs developed for oncology, though selectivity remains a challenge due to functional redundancy in this protein family
Induction of apoptosis by blocking anti-apoptotic BCL-2 family proteins via BH3-mimetic small molecules (drugs mimic BH3-only protein interactions, antagonize BCL-2-like proteins, and trigger cell death in cancer cells) Possible modulation of cell survival pathways in neurons and germ cells through genetic or protein inhibition
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL-2-like protein 2 (BCL2L2).